U.S. Department of Health and Human Services
James Balow
 

 Contact Info

 
Tel: 301-496-4181
Email: jimb@mail.nih.gov
 

 Select Experience

 
  • Clinical Immunology FellowshipNIAID, NIH1972–1975
  • Internal Medicine and Nephrology FellowshipsGeorgetown University1969–1972
  • M.D.University of Minnesota1968
  • B.S.College of St. Thomas1964
 

 Related Links

 

James E. Balow, M.D.

Clinical Director, Division of Intramural Research
Director of Translational Research, Division of Intramural Research​
Senior Investigator, Kidney Disease Section, Kidney Disease Branch

Specialties: Clinical Research​​

James E. Balow, M.D.

Senior Investigator, Kidney Disease SectionKidney Diseases Branch
Clinical Director, Division of Intramural Research
Director of Translational Research, Division of Intramural Research
Clinical Director, Office of Clinical Director
Specialties
  • Clinical Research
  • Nephrology
Research Summary/In Plain Language

Research Summary

Current Research

The focus of our research is the natural history, pathogenesis, and treatment of immunologically mediated glomerular diseases, particularly lupus nephritis and membranous nephropathy. Previous findings from our research section have demonstrated that intermittent pulse cyclophosphamide therapy has the highest therapeutic index among currently available immunosuppressive drug therapies in the treatment of proliferative forms of lupus nephritis.

In light of the intrinsic risk of gonadal toxicity of pulse cyclophosphamide therapy, we are conducting studies designed to examine the efficacy and toxicity profile of alternative immunomodulating agents, particularly monoclonal antibodies, such as rituximab, calcineurin inhibitors, signaling pathway inhibitors,and antimetabolite drugs.

Recent clinical research of our group has been focused on primary membranous nephropathy, a chronic, autoimmune glomerular disease caused by autoantibodies to constitutive antigens of the capillary wall podocytes.  Membranous nephropathy is manifested by protracted edema due to nephrotic proteinuria and is associated with substantive morbidity from secondary cardiovascular disease and progressive loss of renal function.  Most treatment regimens used in the clinic have been only partially efficacious, often of limited long-term effectiveness, and associated with intrusive side effects.   

Our group has recently completed a pilot study examining the effects of a novel immunosuppressive drug regimen combining cyclosporine and the monoclonal antibody, rituximab, for treating primary membranous nephropathy.  This regimen targets both the T-cell and B-cell limbs of the immune system, both of which contribute to the autoimmune pathogenesis of this disease.  Induction therapy included combination of rituximab and cyclosporine for 6 months, followed by a maintenance phase of additional doses of rituximab while tapering cyclosporine to discontinuance over several months.  Sustained remissions of proteinuria occurred at higher rates than historical controls.  Parallel decreases in titers of autoantibodies to glomerular antigens supported the postulated mechanism of action for the effects of this combination therapy.  [Citation:  Waldman M, Beck LH, Braun M, Wilkins K, Balow JE, Austin HA III.  Membranous nephropathy: pilot study of a novel regimen combining cyclosporine and rituximab. KI Reports 2016; 1:73-84]

Need for Further Study

Our pilot study of the novel regimen of cyclosporine and rituximab has yielded results that suggests that this therapeutic strategy may have improved efficacy over most conventional treatments for membranous nephropathy.  However, our results must be viewed as preliminary and will require validation in randomized clinical trials.  Our pilot study data will inform both the design and power calculations for these prospective, randomized clinical trials.